Proteome Sciences plc

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, 0QNO.L has a market cap of 39.1B. Regarding current trading prices, PRM.L is priced at £3.04, while 0QNO.L trades at £573.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas 0QNO.L's P/E ratio is 14.50. In terms of profitability, PRM.L's ROE is +0.58%, compared to 0QNO.L's ROE of +0.07%. Regarding short-term risk, PRM.L is more volatile compared to 0QNO.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check 0QNO.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, 0KHE.L has a market cap of 10.3B. Regarding current trading prices, PRM.L is priced at £3.04, while 0KHE.L trades at £87.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas 0KHE.L's P/E ratio is 14.25. In terms of profitability, PRM.L's ROE is +0.58%, compared to 0KHE.L's ROE of +0.04%. Regarding short-term risk, PRM.L is more volatile compared to 0KHE.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check 0KHE.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, IDHC.L has a market cap of 208.1M. Regarding current trading prices, PRM.L is priced at £3.04, while IDHC.L trades at £0.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas IDHC.L's P/E ratio is 8.95. In terms of profitability, PRM.L's ROE is +0.58%, compared to IDHC.L's ROE of +0.24%. Regarding short-term risk, PRM.L is more volatile compared to IDHC.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check IDHC.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, 0G8X.L has a market cap of 186.1M. Regarding current trading prices, PRM.L is priced at £3.04, while 0G8X.L trades at £0.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas 0G8X.L's P/E ratio is -0.06. In terms of profitability, PRM.L's ROE is +0.58%, compared to 0G8X.L's ROE of -5.30%. Regarding short-term risk, PRM.L is more volatile compared to 0G8X.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check 0G8X.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, DXRX.L has a market cap of 112.8M. Regarding current trading prices, PRM.L is priced at £3.04, while DXRX.L trades at £133.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas DXRX.L's P/E ratio is -66.75. In terms of profitability, PRM.L's ROE is +0.58%, compared to DXRX.L's ROE of -0.04%. Regarding short-term risk, PRM.L is more volatile compared to DXRX.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check DXRX.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, AGL.L has a market cap of 19.4M. Regarding current trading prices, PRM.L is priced at £3.04, while AGL.L trades at £6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas AGL.L's P/E ratio is -1.20. In terms of profitability, PRM.L's ROE is +0.58%, compared to AGL.L's ROE of -0.66%. Regarding short-term risk, PRM.L is more volatile compared to AGL.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check AGL.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, YGEN.L has a market cap of 16.4M. Regarding current trading prices, PRM.L is priced at £3.04, while YGEN.L trades at £0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas YGEN.L's P/E ratio is -0.51. In terms of profitability, PRM.L's ROE is +0.58%, compared to YGEN.L's ROE of -0.06%. Regarding short-term risk, PRM.L is more volatile compared to YGEN.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check YGEN.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, ABDX.L has a market cap of 12.6M. Regarding current trading prices, PRM.L is priced at £3.04, while ABDX.L trades at £6.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas ABDX.L's P/E ratio is -6.50. In terms of profitability, PRM.L's ROE is +0.58%, compared to ABDX.L's ROE of -0.60%. Regarding short-term risk, PRM.L is more volatile compared to ABDX.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check ABDX.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, VRCI.L has a market cap of 8.3M. Regarding current trading prices, PRM.L is priced at £3.04, while VRCI.L trades at £0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas VRCI.L's P/E ratio is -0.28. In terms of profitability, PRM.L's ROE is +0.58%, compared to VRCI.L's ROE of -1.33%. Regarding short-term risk, PRM.L is more volatile compared to VRCI.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check VRCI.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, GDR.L has a market cap of 7.3M. Regarding current trading prices, PRM.L is priced at £3.04, while GDR.L trades at £1.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas GDR.L's P/E ratio is -0.59. In terms of profitability, PRM.L's ROE is +0.58%, compared to GDR.L's ROE of -1.75%. Regarding short-term risk, PRM.L is more volatile compared to GDR.L. This indicates potentially higher risk in terms of short-term price fluctuations for PRM.L.Check GDR.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, GENI.L has a market cap of 5.2M. Regarding current trading prices, PRM.L is priced at £3.04, while GENI.L trades at £1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas GENI.L's P/E ratio is -0.60. In terms of profitability, PRM.L's ROE is +0.58%, compared to GENI.L's ROE of -2.25%. Regarding short-term risk, PRM.L is less volatile compared to GENI.L. This indicates potentially lower risk in terms of short-term price fluctuations for PRM.L.Check GENI.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, LLA.L has a market cap of 1.3M. Regarding current trading prices, PRM.L is priced at £3.04, while LLA.L trades at £5.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas LLA.L's P/E ratio is -0.42. In terms of profitability, PRM.L's ROE is +0.58%, compared to LLA.L's ROE of N/A. Regarding short-term risk, PRM.L is less volatile compared to LLA.L. This indicates potentially lower risk in terms of short-term price fluctuations for PRM.L.Check LLA.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, LLAI.L has a market cap of 1.3M. Regarding current trading prices, PRM.L is priced at £3.04, while LLAI.L trades at £4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas LLAI.L's P/E ratio is -0.35. In terms of profitability, PRM.L's ROE is +0.58%, compared to LLAI.L's ROE of -0.56%. Regarding short-term risk, PRM.L is less volatile compared to LLAI.L. This indicates potentially lower risk in terms of short-term price fluctuations for PRM.L.Check LLAI.L's competition here

PRM.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PRM.L stands at 9M. In comparison, SBI.L has a market cap of 0. Regarding current trading prices, PRM.L is priced at £3.04, while SBI.L trades at £115.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PRM.L currently has a P/E ratio of -3.04, whereas SBI.L's P/E ratio is N/A. In terms of profitability, PRM.L's ROE is +0.58%, compared to SBI.L's ROE of +0.42%. Regarding short-term risk, Volatility data is not available for a full comparison. PRM.L has daily volatility of 18.30 and SBI.L has daily volatility of N/A.Check SBI.L's competition here